	Programme Outline		
	Sunday 11 September 2022		
17:00-18:30	Registration and Welcome Drinks Reception  Room: Palavela		
		nh a # 2022	
	Monday 12 Septer	nber 2022	
09:00-10:30	OPENING PLENARY SESSION		
	Chair: Gregory A. Poland, Paolo Bonnani Room: Garda		
09:00-09.10	Opening remarks		
	Conference Chair and Local Chair, Gregory A. Poland a	nd Paolo Bonanni	
09.10-09:50	KN01 - Winner of the Schneerson-Robbins Prize		
	The trillion dollar vaccine gap		
09:50-10:30	Rino Rappuoli, GlaxoSmithKline Vaccines, Italy  KN02 - Winner of Edward Jenner Vaccine Prize		
09.30-10.30	My life with Varicella-Zoster virus		
	Myron Levin, University of Colorado, USA		
10:30-11:00	Refreshment break		
11.00 11 20	Room: Palavela		
11:00-11:30	Chair: Gragony A. Poland		
	Chair: Gregory A. Poland  Room: Garda		
11:00-11:30	KN03 - Winner of the Early Career Scientist Award		
	Immune responses induced by SARS-CoV-2 vaccinations		
44.30.43.00	Daniela Weiskopf, La Jolla Institute for Immunology, U		
11:30-13:00	BREAKOUT SESSION 1 T-cells and Viral Vaccines (COVID and Others)	BREAKOUT SESSION 2 Novel Vaccine Platforms	
	Chair: Ivan Hung, Rick Kennedy	Chairs: Angie Rasmussen, Myron Levin	
	Room: Garda	Room: Dolomiti	
11:30-12:00	INV01 - Immune responses against virus-infections	INV02 - Trivalent HSV-2 mRNA-lipid nanoparticle	
	and vaccinations: Identification of biomarkers of	vaccine for preventing genital herpes	
	susceptibility to improve vaccination strategies in older adults	Harvey Freidman, University of Pennsylvania, USA	
	Alper Cevirgel <sup>1</sup> , Sudarshan Shetty <sup>2,1</sup> , Martijn Vos <sup>1</sup> ,		
	Nening Nanlohy <sup>1</sup> , Lisa Beckers <sup>1</sup> , Elske Bijvank <sup>1</sup> ,		
	Nynke Rots <sup>1</sup> , Josine van Beek <sup>1</sup> , Anne Marie		
	Buisman <sup>1</sup> , <u>Debbie van Baarle</u> <sup>2,1</sup>		
	<sup>1</sup> National Institute for Public Health and the Environment, The Netherlands. <sup>2</sup> University Medical		
	Center, The Netherlands		
12:00-12:15	O1.1 - Cellular and humoral responses to SARS-CoV-	O2.1 - Multiple exposure to SARS-CoV-2 enhances	
	2 vaccination in immunosuppressed patients.	cross-neutralizing antibodies to antigenically distinct,	
	<u>Dinesh Mohanrai</u> <sup>1</sup> , Alison Whitelegg <sup>2</sup> , Satbeer	non-exposed variants	
	Singh <sup>3</sup> , Alun Gordon <sup>3</sup> , Samuel Baldwin <sup>3</sup> <sup>1</sup> The University of Manchester Faculty of Biology	Annika Rössler <sup>1</sup> , Antonia Netzl <sup>2</sup> , Ludwig Knabl <sup>3</sup> , Helena Schäfer <sup>1</sup> , Samuel H. Wilks <sup>2</sup> , David Bante <sup>1</sup> ,	
	Medicine and Health, UK. <sup>2</sup> University Hospital	Barbara Falkensammer <sup>1</sup> , Wegene Borena <sup>1</sup> , Dorothee	
	Southampton NHS Foundation Trust, UK <sup>3</sup> Portsmouth	von Laer¹, Derek Smith², <u>Janine Kimpel¹</u>	
	Hospitals University NHS Trust, UK	¹Institute of Virology, Department of Hygiene,	
		Microbiology and Public Health, Medical University	
		of Innsbruck, Innsbruck, Austria. <sup>2</sup> University of Cambridge, Center for Pathogen Evolution,	
		Department of Zoology, Cambridge, UK.	
		³Tyrolpath Obrist Brunhuber GmbH, Zams, Austria	
12:15-12:30	O1.2 - SARS-CoV-2 infection in vaccinees induces	O2.2 - A Novel Intranasal Protein Subunit Vaccine for	
	virus-specific nasal-resident CD8 and CD4 T cells of	Pseudomonas aeruginosa  Adius Katsoff <sup>1</sup> Eman Barahim <sup>1</sup> Christina Toumanios <sup>1</sup>	
	broad specificity  Joey Ming Er Lim <sup>1</sup> , Anthony Tanoto Tan <sup>1</sup> , Nina Le	Adiya Katseff <sup>1</sup> , Eman Barahim <sup>1</sup> , Christina Toumanios <sup>1</sup> , Alison McCormick <sup>2</sup> , Paul Arnaboldi <sup>1,3,4</sup>	
	Bert <sup>1</sup> , Shou Kit Hang <sup>1</sup> , Adeline	<sup>1</sup> New York Medical College, Valhalla, USA. <sup>2</sup> Touro	
	Chia <sup>1</sup> , Jenny Guek Hong Low <sup>2</sup> , Antonio Bertoletti <sup>1</sup>	University, California, Vallejo, USA. <sup>3</sup> Biopeptides, Corp.,	

	<sup>1</sup> Duke-NUS Medical School, Singapore, Singapore. <sup>2</sup> Singapore General Hospital, Singapore, Singapore	East Setauket, USA. ⁴Lovelace Biomedical Research Institute, Albuquerque, USA
12:30-12:45	O1.3 - Generation of multiple SARS-CoV2-specific immune response in vivo by epitope-based nanoparticle vaccine in humanized ACE2 transgenic mouse model  Iliyan Manoylov <sup>1</sup> , Nikolina Mihaylova <sup>1</sup> , Nikola Ralchev <sup>1</sup> , Silviya Bradyanova <sup>1</sup> , Irini Doytchinova <sup>2</sup> , Andrey Tchorbanov <sup>1</sup> <sup>1</sup> Institute of Microbiology, Bulgarian Academy of Sciences, Bulgaria. <sup>2</sup> Faculty of Pharmacy, Medical University of Sofia, Bulgaria	O2.3 - Linear DNA amplicons as veterinary Covid-19 vaccine candidate  Antonella Conforti <sup>1</sup> , Erika Salvatori <sup>2</sup> , Lucia Lione <sup>2</sup> , Mirco Compagnone <sup>3</sup> , Eleonora Pinto <sup>2</sup> , Brian Viscount <sup>4</sup> , James Hayward <sup>4</sup> , Clay Shorrock <sup>4</sup> , Diego Diel <sup>5</sup> , Fabio Palombo <sup>3</sup> , Joe Impellizeri <sup>6</sup> , Luigi Aurisicchio <sup>1,2</sup> 1 Evvivax, Rome, Italy. Takis, Rome, Italy. Neomatrix, Rome, Italy. Adnas, New York, USA. Cornell University, New York, USA. Guardian Veterinary Services, New York, USA
12:45-13:00	O1.4 - Kinetics of the B and T-cell immune responses following the third dose of SARS-CoV-2 mRNA vaccines in patients with rheumatoid arthritis: a multicenter study  Alessandra Aiello¹, Andrea Picchianti-Diamanti², Chiara Farroni¹, Bruno Laganà², Chiara Agrati³, Anna Rosa Garbuglia⁴, Silvia Meschi⁴, Daniele Lapa⁴, Gilda Cuzzi¹, Linda Petrone¹, Valentina Vanini¹,⁵, Andrea Salmi¹, Anna Maria Gerarda Altera¹, Vincenzo Puro⁶, Palma Scolieri³, Vincenzo Bruzzese⁵, Maurizio Benucci³, Fabrizio Cantiniց¸, Emanuele Nicastri¹o, Delia Goletti¹ (not registered/no show)  ¹Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy. ² "Sapienza" University, S. Andrea University Hospital, Italy ³Laboratory of Cellular Immunology, IRCCS, Italy. ⁴Laboratory of Virology, IRCCS, Italy. ⁵UOS Professioni Sanitarie Tecniche, IRCCS, Italy. ⁵UOC Emerging Infections and Centro di Riferimento AIDS (CRAIDS), IRCCS, Italy. ¹U.O.C. Hospital S. Spirito-Nuovo Regina Margherita, Italy.  ®Rheumatology Unit, S.Giovanni di Dio Hospital, Italy. ¹Rheumatology Department, Hospital of Prato, Italy. ¹Clinical Division of Infectious Diseases, IRCCS, Italy	O2.4 - Poly-γ-glutamic acid/Alum adjuvanted pH1N1 vaccine-immunized aged mice exhibit a significant increase in vaccine efficacy with a decrease in ageassociated CD8+ T cell proportion in splenocytes Jihyun Yang, Jaemoo Kim, HARYOUNG POO KRIBB, Daejeon, Republic of Korea
13:00-14:00	Lunch Room: Palavela	
14:00-15:30	BREAKOUT SESSION 3 Vaccines against Vector Borne Diseases and NTD's Chairs: Tony Fooks, Maria Elena Bottazzi Room: Garda	BREAKOUT SESSION 4  Vaccine Hesitancy – education, communication, perceptions, protection and disease, emotional response  Chair: Greg Poland, Jen Nelson  Room: Dolomiti
14:00-14:30	INV03 - Naturally acquired and vaccine induced immunity to Ebola virus Miles Carroll, Oxford University, UK	INV04 - Addressing Vaccine Hesitancy: Integrating the Vaccine Trust Gauge and effective communication to advance confidence and uptake  Scott Ratzan, CUNY School of Public Health and Health Policy, New York, USA

14:30-14:45	O3.1 - Optimisation of dengue virus maturation and implications on vaccine efficacy in mice  Connor Scott <sup>1</sup> , Alberto Amarilla <sup>1</sup> , Summa Bibby <sup>1</sup> ,  Natalee Newton <sup>1</sup> , Roy Hall <sup>1,2</sup> , Jody Hobson-Peters <sup>1,2</sup> ,  David Muller <sup>1</sup> , Keith Chappell <sup>1,2</sup> , Paul Young <sup>1,2</sup> ,  Naphak Modhiran <sup>1</sup> , Daniel Watterson <sup>1,2</sup> <sup>1</sup> School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia. <sup>2</sup> Australian Infectious Disease Research Centre, The University of Queensland, St Lucia, Australia	O4.1 - Identifying factors that characterize resilient immunization programs: a systematic scoping review.  Aomesh Bhatt <sup>1</sup> , Luke Baxter <sup>1</sup> , Lindsay Hermany <sup>2</sup> , Alexandra Bhatti <sup>2</sup> , Amanda Eiden <sup>2</sup> , Rachel Mitrovich <sup>2</sup> , Mark Connolly <sup>3</sup> , Mawuli Nyaku <sup>2</sup> , Rebeccah Slater <sup>1</sup> <sup>1</sup> University of Oxford, Oxford, UK. <sup>2</sup> Merck & Co, Inc, Kenilworth, USA. <sup>3</sup> GMAS, Charlotte, USA
14:45-15:00	O3.2 - Evaluating the efficacy and correlates of protection for an insect-specific flavivirus vectored Zika vaccine.  Albert Auguste, Danielle Porier, Manette Tanelus Virginia Tech, USA	O4.2 - Community-specific personal stories improve HPV vaccine attitudes in a Christian population in the United States David Redd, Jamie Jensen, Chantel Sloan-Aagard, Brian Poole, Brigham Young University, Provo, USA
15:00-15:15	O3.3 - Baseline human immune determinants of yellow fever live-attenuated vaccine immunogenicity  Justin Ooi¹, Clara Koh¹, Eugenia Ong², Candice Chan³, Esther Gan¹, Noor Zayanah Hamis¹, Laura Rivino⁴, Jenny Low³, Eng Eong Ooi¹,²,²,⁵, Kuan Rong Chan¹¹Duke-NUS Medical School, Singapore. ²Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore. ³Department of Infectious Diseases, Singapore General Hospital, Singapore. ⁴School of Cellular and Molecular Medicine, University of Bristol, UK. ⁵Saw Swee Hock School of Public Health, National University of Singapore, Singapore	O4.3 - Vaccine wars in the 21st century: A clash of world views Gregory A Poland, Mayo Clinic, USA
15:15-15:30	O3.4 - A single nucleotide U59C substitution in the dengue virus 5' untranslated region destabilized an attenuating mutation in mosquitoes.  Amanda Bifani¹, Hwee Cheng Tan¹, Dorothy Ng², Kitti Chan¹, Subhash Vasudevan¹, Milly Choy¹, Eng Eong Ooi¹¹Duke-NUS Medical School, Singapore, ²SingHealth, Singapore	
15:30-16:00	Refreshment break Room: Palavela	
16:00-17:30	BREAKOUT SESSION 5 New Regulatory Pathways for Urgent Vaccines Chairs: Ken Ishii, Carlos del Rio Room: Garda	BREAKOUT SESSION 6 Vaccine Platforms, Vectors and Delivery Systems (patches, time release) Chairs: Ivan Hung, Danny Altmann Room: Dolomiti
16:00-16:30	INV05 - Immunobridging strategies for urgent vaccines: reality or fantasy? Phil Krause Independent Consultant, USA	*INV06 - Improving (COVID) vaccines by intradermal self-administration  Yotam Levin, Dean Kamen, Efrat Kochba  NanoPass, Israel  One presentation will be given remotely
16:30-16:45	O5.1 - How to accelerate the supply of vaccines to all populations worldwide - A regulatory perspective  Mic McGoldrick <sup>1</sup> , Thierry Gastineau <sup>2</sup> <sup>1</sup> International Federation of Pharmaceutical Manufacturers and Associations, Switzerland. <sup>2</sup> Vaccines Europe, Belgium	O6.1 - Development of Heat Stable Oral Vaccines for Coronavirus  John Howard  Applied Biotechnology Institute Inc., USA
16:45-17:00	O5.2 Development of a revised 'Barriers to Care' conceptual framework and its application to vaccination policy and practice during the COVID-19 pandemic  Anna Larson, Rachel Mitrovich, Merck & Co., Inc., USA	O6.2 Availability of the highly attenuated replication-competent vaccinia virus strain LC16m8Δ as a COVID-19 vaccine platform <u>Akihiko Sakamoto</u> <sup>1</sup> , Hiroaki Osawa <sup>1</sup> , Tetsushi Mizuno <sup>1</sup> , Hinata Hashimoto <sup>1</sup> , Kyouhei Yamagata <sup>1</sup> , Saya Yamauchi <sup>1</sup> , Keigo Mitsuhashi <sup>1</sup> , Ryohei Ogawa <sup>2</sup> , Mitsuhiro Iyori <sup>1</sup> , Hisatoshi Shida <sup>3</sup> , Shigeto Yoshida <sup>1</sup> <sup>1</sup> Kanazawa University, Ishikawa, Japan. <sup>2</sup> Toyama University, Japan. <sup>3</sup> Hokkaido University, Japan

17:00-17:15 17:15-17:30	O5.3 - Critical success factors for conducting human challenge trials for vaccine development in lowand middle-income countries.  Keiko Msusa <sup>1</sup> , Taryn Rogalski-Salter <sup>2</sup> , Henshaw Mandi <sup>3</sup> , Ralf Clemens <sup>1</sup> <sup>1</sup> University of Siena, Institute for Global Health, Italy <sup>2</sup> Bill and Melinda Gates Medical Research Institue, USA. <sup>3</sup> Coalition for Epidemic Preparedness Innovations, Norway  O5.4 - ACE2 inhibition assay as an effective surrogate for SARS-CoV-2 neutralisation Tom Tipton <sup>1</sup> , Stephanie Longet <sup>1</sup> , Stephen Laidlaw <sup>1</sup> , Dung Nguyen <sup>1</sup> , Susanna Dunachie <sup>1</sup> , Paul Klanerman <sup>1</sup> , William James <sup>1</sup> , Ellie Barnes <sup>1</sup> , Thushan de Silva <sup>2</sup> , Miles Carroll <sup>1</sup> <sup>1</sup> University of Oxford, UK. <sup>2</sup> University of Sheffield, UK	O6.3 - GMMA for the development of an O-antigen based vaccine against Shigella Francesca Mancini, Roberta Di Benedetto, Valentina Caradonna, Maria Grazia Aruta, Carlo Giannelli, Mariagrazia Pizza, Omar Rossi, Francesca Micoli GSK Vaccines Institute for Global health, Italy  O6.4 - Env-2dCD4S60C complexes elicit potent, broadly neutralizing antibodies against clinically relevant viruses in Chines-origin rhesus macaques. Roberto Carlos Rebelo Pereira, Mark Andrew Killick, Maria Antonia Papathanasopoulos HIV Pathogenesis Research Unit, University of the Witwatersrand, South Africa
17:30-19:00	Drinks Reception, Poster Session 1  Room: Palavela  No shows: P1.06, P1.14, P1.21)	witwaterstand, South Africa
18:30-19:30	Meet the Editors Session Chair: Greg Poland Room: Garda	Scott Ratzan Roundtable: Statement on Multisectoral Actions for Building Trust to Promote Vaccine Acceptance Chair: Scott Ratzan, Lauren Rauh Room: Dolomiti
	Tuesday 13 Septer	mber 2022
08:00-09:00	Researcher Academy – Early/Mid Career Fundamentals of Peer Review Chair: Dior Beerens Room: Garda	Infectious Diseases Clinical Research Consortium (IDCRC) Symposium: New Studies from the Vaccine and Treatment Evaluation Units (VTEUs) Chair: Paul Spearman Room: Dolomiti
09:00-11:00	PLENARY SESSION 2 COVID and COVID Vaccines Chair: Greg Poland, Carlos del Rio Room: Garda	Noom. Dolomiti
09:00-09.30	KN04 - Academic Creativity, Strategic Alliances and Di CORBEVAX, a protein subunit COVID-19 vaccine Maria Elena Bottazzi, Baylor College of Medicine, USA	iplomacy: Behind the scenes for the development of
09:30-10.00	KN05 - Antibody as a Correlate of Protection to SARS- David Goldblatt, University College London, UK Presentation will be given remotely	CoV-2 following natural infection and vaccination
10:00-10:30	KN06 - SARS-CoV-2 human infection challenge to acce Christopher Chiu, Imperial College London, UK	elerate vaccine development
10:30-11:00	Panel Discussion All speakers, COVID and next steps	
11:00-11:30	Refreshment break Room: Palavela	
11:30-13:00	BREAKOUT SESSION 7 New Pneumococcal and Meningococcal Vaccines Chairs: Ivan Hung, Carlos del Rio Room: Garda	BREAKOUT 8 Celebrating successes (but you can't stop there) Polio, measles, positive impacts and the role of Clinical Trial networks Chair: Helena Maltezou, Rick Kennedy Room: Dolomiti
11:30-12:00	INV07 - Development of low-cost pneumococcal and meningococcal vaccines for low and middle-income countries: lessons learned  Mark Alderson PATH, USA	INV08 - Eradicating Poliovirus: how much is still missing? <u>Silvio Tafuri</u> , Francesco Paolo Bianchi  Aldo Moro University of Bari, Italy
12:00-12:15	O7.1 - A nanotechnological approach to potentiate the immunogenicity of pneumococcal glycoconjugate vaccines  Maruthi Prasanna <sup>1,2</sup> , Rubén Varela Calvino <sup>2</sup> ,  Daphnée Soulard <sup>3</sup> , Lorenzo Albertazzi <sup>4</sup> , Annie Lambert <sup>1</sup> , Sylvia Pujals <sup>4</sup> , François Trottein <sup>3</sup> , Emilie Camberlein <sup>1</sup> , Noemi Csaba <sup>2</sup> , Cyrille Grandjean <sup>1</sup>	O8.1 - Morbidity and absenteeism among healthcare personnel in the context of a mandatory COVID-19 vaccination policy Helena Maltezou, National Public Health Organization in Athens, Greece

University of Santiago de Compostela, Spain. <sup>3</sup> CIIL Inserm U1019, CNRS UMR 8204 Pasteur Institute of	
Lille, France. <sup>4</sup> Nanoscopy for Nanomedicine, Institute for Bioengineering of Catalonia, Spain	
5-12:30 O7.2 Is the more the better? Assessing whether	
sugar-coating pneumococcal bioconjugates boosts their immunogenicity	
Marta Mauri <sup>1</sup> , Emily Kay <sup>1</sup> , Giuseppe Ercoli <sup>2</sup> , Jeremy	
Brown <sup>2</sup> , Brendan Wren <sup>1</sup> <sup>1</sup> LSHTM, UK. <sup>2</sup> UCL, UK	
0-12:45 O7.3 Using LASSO regression to estimate the O8.2 - A cross-sectional analysis of COVID	D-19 vaccine
population-level impact of pneumococcal conjugate   clinical trials in Africa	3 - 1 11
vaccines <u>Anabelle Wong<sup>1,2</sup>, Sarah Kramer<sup>1</sup>, Marco</u> <u>Lindi Mathebula</u> <sup>1</sup> , Charles S. Wiysonge <sup>1,2,3</sup> Ndwandwe <sup>1 1</sup> Cochrane South Africa, South	
Piccininni <sup>3,4</sup> , Jessica Rohmann <sup>3,4</sup> , Tobias Kurth <sup>2</sup> , Sylvie Medical Research Council, South Africa. <sup>2</sup> C	-
Escolano <sup>5</sup> , Matthieu Domenech de Cellès <sup>1</sup> Evidence-based Health Care, Stellenbosch	
<sup>1</sup> Max Planck Institute for Infection Biology, Germany. South Africa. <sup>3</sup> Division of Epidemiology an	•
<sup>2</sup> Charité – Universitätsmedizin Berlin, Germany. University of Cape Town., South Africa	
<sup>3</sup> Institute of Public Health, Charité –	
Universitätsmedizin, Berlin, Germany. ⁴Center for	
Stroke Research Berlin, Germany. <sup>5</sup> Université Paris-	
Saclay, UVSQ, Université Paris-Sud CESP, France  5-13:00 O7.4 - Effectiveness and safety of meningococcal O8.4 - Strategic introduction of the RTS,S	S/ASO1 malaria
quadrivalent conjugate vaccines: a systematic vaccine relative to scale-up of existing in	
review Hillary M. Topazian, Nora Schmit, Ines Ge	
Massimiliano Panella, Chiara Sacchi, Gaia Broglia, Giovanni D. Charles, Azra C. Ghani, Peter	•
Fabrizia Risi, Fancesco Barone Adesi, <u>Andrea Conti</u> Imperial College London, UK	
Università degli Studi del Piemonte Orientale,	
Novara, Italy	
0-14:00 Lunch Break Room: Palavela	
BREAKOUT SESSION 9 BREAKOUT SESSION 10	
Influenza, new adjuvants including Laser mRNA Vaccines – the future and sustaina	ability
Chairs: Florian Krammer, Ken Ishii Chairs Angie Rasmussen, Amy Chung	
Room: Garda Room: Dolomiti	
0-14.30 INV09 - Maturation of B cell Responses to mRNA INV10 - mRNA Variant Boosting on Immu	-
Vaccines in Humans  Protection in NHP: How we Move Forward Control of the National Alicenses and Police and Po	rd With
Ali Ellebedy, Washington University School of  Medicine, USA  Vaccine Design and Delivery  Robert Seder, Vaccine Research Center, N	JIAID IISA
Presentation will be given remotely	VIAID, USA
0-14.45 O9.1 - Characterization and comparison of novel O10.1 - A trans-amplifying RNA vaccine c	candidate
adjuvants for a prefusion clamped MERS vaccine induces a specific immune response that	
<u>Jake S. O'Donnell<sup>1,2</sup></u> , Ariel Isaacs <sup>1,2</sup> , Virginie Jakob <sup>3</sup> , against chikungunya virus infections.	
Celia Lebas <sup>3</sup> , James Barnes <sup>4</sup> , Patrick C. Reading <sup>4</sup> , Paul  Christin Schmidt <sup>1</sup> , Erik Haefner <sup>1</sup> , Julia Ger	
R. Young <sup>5</sup> , Daniel Watterson <sup>5</sup> , Patrice M. Dubois <sup>3</sup> ,  Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Ugur Sahin <sup>2</sup> , Mario Perkovic <sup>2</sup> , Beissert <sup>2</sup> , Mario Perkovic <sup></sup>	
Nicolas Collin <sup>3</sup> , Keith J. Chappell <sup>1,5,6</sup> <sup>1</sup> The Australian  Institute for Bioengineering and Nanotechnology,  Germany. <sup>2</sup> TRON (Translational Oncology)	
Australia. <sup>2</sup> The School of Chemistry and Molecular University Medical Center), Johannes Gute	
Biosciences, The University of Queensland, Australia. University Mainz, Germany	
<sup>3</sup> Vaccine Formulation Institute, Switzerland. <sup>4</sup> The	
WHO Collaborating Centre for Reference and	
Research on Influenza, at The Peter Doherty Institute	
for Infection and Immunity, Australia. <sup>5</sup> The School of	
Chemistry and Molecular Biosciences, The University of Queensland, Australia. <sup>6</sup> Australian Infectious	
ו Uisease kesearch Centre. ine University of	
Disease Research Centre, The University of Queensland, Australia	
	nses are
Queensland, Australia  5-15:00 O9.2 - Development and implementation of the global Influenza Vaccines R&D Roadmap Variably induced in response to SARS-Co	V-2 mRNA
Queensland, Australia  5-15:00 O9.2 - Development and implementation of the global Influenza Vaccines R&D Roadmap Kristine Moore <sup>1</sup> , Julie Ostrowsky <sup>1</sup> , Anje Mehr <sup>1</sup> , Vaccination and are associated with prot	V-2 mRNA
Queensland, Australia  5-15:00 O9.2 - Development and implementation of the global Influenza Vaccines R&D Roadmap Kristine Moore <sup>1</sup> , Julie Ostrowsky <sup>1</sup> , Anje Mehr <sup>1</sup> , Angela Ulrich <sup>1</sup> , Michael Osterholm <sup>1</sup> , Joseph Bresee <sup>2</sup> , subsequent infection  O10.2 - Systemic and mucosal IgA responsation variably induced in response to SARS-Colvation and are associated with protessing subsequent infection	V-2 mRNA tection against
Queensland, Australia  5-15:00 O9.2 - Development and implementation of the global Influenza Vaccines R&D Roadmap Kristine Moore <sup>1</sup> , Julie Ostrowsky <sup>1</sup> , Anje Mehr <sup>1</sup> , Angela Ulrich <sup>1</sup> , Michael Osterholm <sup>1</sup> , Joseph Bresee <sup>2</sup> , Christopher Chadwick <sup>3</sup> , Martin Friede <sup>3</sup> , Bruce Gellin <sup>4</sup> ,  Salma Sheikh-Mohamed <sup>1</sup> , Gary Chao <sup>1</sup> , Bar	V-2 mRNA tection against weleta Isho <sup>1</sup> ,
Queensland, Australia  5-15:00 O9.2 - Development and implementation of the global Influenza Vaccines R&D Roadmap Kristine Moore <sup>1</sup> , Julie Ostrowsky <sup>1</sup> , Anje Mehr <sup>1</sup> , Angela Ulrich <sup>1</sup> , Michael Osterholm <sup>1</sup> , Joseph Bresee <sup>2</sup> , subsequent infection  O10.2 - Systemic and mucosal IgA responsation variably induced in response to SARS-Colvation and are associated with protessing subsequent infection	V-2 mRNA tection against weleta Isho <sup>1</sup> , Gingras <sup>4</sup> , Jen

	Switzerland. <sup>4</sup> The Rockefeller Foundation, USA. <sup>5</sup> Wellcome Trust, UK. <sup>6</sup> Sabin Vaccine Institute, USA. <sup>7</sup> Centers for Disease Control and Prevention, USA	Medical Centre, Israel. <sup>3</sup> St. Michael's Hospital, Canada. <sup>4</sup> Mount Sinai, Canada
15:00-15:15	O9.3 - Transcriptomic signatures of humoral response to high dose and adjuvanted influenza vaccine in the elderly population Inna Ovsyannikova <sup>1</sup> , Richard Kennedy <sup>2</sup> , Gregory Poland <sup>2 1</sup> Mayo Clinic Vaccine Research Group, USA. <sup>2</sup> Mayo Clinic Vaccine Research Group, USA	O10.3 - Safety and Immunogenicity of mRNA-1345, an mRNA-Based Vaccine Against Respiratory Syncytial Virus in Older Adults  Grace Chen <sup>1</sup> , Runa Mithani <sup>1</sup> , Archana Kapoor <sup>1</sup> , Sophia Lu <sup>1</sup> , Christine A. Shaw <sup>1</sup> , Sonia K. Stoszek <sup>1</sup> , Allison August <sup>2</sup> <sup>1</sup> Moderna, Inc., USA. <sup>2</sup> Moderna, Inc, USA
15:15-15:30	O9.4 -Innovative multi-component adjuvants induce sustained multi-functional anti-Influenza A responses in guinea pigs  Emmelie Eckhardt¹, Ger Van Zandbergen², Max  Bastian¹¹Friedrich-Loeffler-Institut, Germany. ²Paul-Ehrlich-Institut, Germany	O10.4 - COVID-19 mRNA vaccination drives differential mucosal neutralising antibody profiles in naïve and SARS-CoV-2 previously infected individuals  Stephanie Longet¹, Alexander Hargreaves¹, Saoirse Healy¹, Rebecca Brown², Hailey R Hornsby², Naomi Meardon³, Tom Tipton¹, Eleanor Barnes¹,⁴, Susanna Dunachie¹,⁴,⁵, Christopher JA Duncan⁶,ⁿ, Paul Klenerman¹,⁴, Alex Richter®,ց, Lance Turtle¹o,¹¹, Thushan I de Silva²,³, Miles W Carroll¹  ¹University of Oxford, UK ²University of Sheffield, UK  ³Sheffield Teaching Hospitals NHS Foundation Trust, UK  ⁴Oxford University Hospitals NHS Foundation Trust, UK  ⁵Mahidol-Oxford Tropical Medicine Research Unit, Thailand ⁶Newcastle University, UK ¬Newcastle upon Tyne Hospitals NHS Foundation Trust, UK ®University of Birmingham, UK. 9University Hospitals Birmingham NHS Foundation Trust, UK. ¹¹University of Liverpool, UK  ¹¹Liverpool University Hospitals NHS Foundation Trust, UK
15:30-17.00	Refreshment break and Poster Session 2	
	Room: Palavela No shows: P2.01, P2.05, P2.06, P2.12, P2.31, P2.36, P2.38, P2.60, P2.61)	
17:00-18:30	BREAKOUT SESSION 11 - Panel discussion on Public Health Response in an Age of Politics and Science Scepticism Chairs: Gregory A. Poland and Paolo Bonanni Room: Garda  Reflections on Pandemic Planning and Response: Pareto Efficiency or Nash Equilibrium? Gregory A. Poland Poland	
	Science Communication and Combatting Disinformation About Public Health Angie Rasmussen	
	Crisis communication in the age of social media Carlos del Rio	
	Vaccination policies, issues of accessibility and beyond Helena Maltezou	
10.20.22.00	Discussion and Q&A	
19:30-22:00	Conference Dinner (ticket required)  Wednesday 14 Sept	ombor 2022
08:30-09:30	Hot Topic – Overview and Update on Monkeypox	
	Greg Poland and Rick Kennedy  Room: Garda	
	Monkeypox immunology and vaccines Rick Kennedy	
	An overview of monkeypox epidemiology, clinical presentation, and pandemic control Gregory A. Poland	
	Discussion and Q&A	

Vaccine Safety   Chairs: Jen Nelson, Danny Altmann   Room: Garda	00:20 11:20	DI ENIADY SESSION 2	
Chairs: Jean Nelson, Danny Altmann 80:30-10.00 NNO7 - COVID-19 vaccination, fertility and pregnancy. How could we have done better? Victoria Male, imperial College London, UK NNO8 - Rapid Generation of Vaccine Safety Evidence During COVID-19 Nicola Klein, Kozie Permanente Vectore Study Center, USA 10:30-11:00 NNO9 - Vaccine safety surveillance in low- and middle-income countries Gagandeep Kang, Christion Medical College, India Refreshment break Noom: Polaveid Noom: Polaveid Noom: Polaveid Noom: Polaveid Noom: College Noom: Colle	09:30-11:30	PLENARY SESSION 3 Vaccine Safety	
80.30-10.00  Nord - COVID-19 vaccination, fertility and pregnancy. How could we have done better?  Victoria Male, Impecial College London, UK  10:00-10:30  Nicola Kitein, Koiser Permanente Vaccine Study Center, USA  10:30-11:00  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Refreshment break  Nord - Covid Long Step Study London, UK  Research Center (IMA-CSA), 1900, 18		•	
Victoria Male, Imperial College London, UK   Victoria Male, Imperial College London   Victoria Male, Imperial College London   Victoria Male, Imperial College London   Victoria Male, Imperial College, India   Victoria Male, India   Vic			
10:00-10:30	09.30-10.00	KN07 - COVID-19 vaccination, fertility and pregnancy.	How could we have done better?
Nicola Nicola Nelion, Koiser Permonente Voccine Study Center, USA  11:30-11:30  Refreshment break Room: Balovela Room: Balovela Room: Balovela Room: Garda Hi Topics Chair: Florian Kramer, Rick Kennedy Room: Garda Concern Ashley St. John, Duke – NUS Medical School, Singapore Lindon-Irritation and infactions including covid-19 and other viral infactions with the small epitope phosphorylcholine as antigen lothan Frosteadis Coulin's Tackney Florian Kramer's Number of Hispania University, Sweden Lindon-Irritation Country Irritation and BNT162b2 Zollan Banki, Jose Mateus', Annika Rossier', Helena Schäfer', David Bantel', Iydia Riepler', Alha Grifoni', Alessandro Setta'd, Viviana Simons** Seerort, DI USA.  12:15-12:30  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous Schäfer', David Bantel', Iydia Riepler', Alha Grifoni', Alessandro Setta'd, Viviana Simons** Seerort, DI USA.  12:15-12:30  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous Schäfer', David Bantel', Iydia Riepler', Alha Grifoni', Alessandro Setta'd, Viviana Simons** Seerort, DI USA.  10:10:10:10:10:10:10:10:10:10:10:10:10:1			
11:30-11:00  KN09 - Vaccine safety surveillance in low- and middle-income countries Gagandeep Knag, Christion Medical College, Indio  Refreshment break Room: Redovels  BREAKOUT SESSION 12  Hot Topics Chair: Borlan Krammer, Rick Kennedy Room: Garda  11:30-12:00  Room: Garda  11:30-12:00  Room: Garda  Liverinary and Agriculturally important Vaccines Chairs: Tory Fools, Anny Chung Room: Bolowing Chair Self Singy Fools, Anny Chung Room: Bolowing Chair Self Singy Fools, Anny Chung Room: Bolomiti INV11 - Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern Ashley St. John, Duke – NUS Medical School, Singapore  12:00-12:15  O11.1 - A vaccine candidate against atherosclerosis, chronic Inflammation and Infections including covid-19 and other viral infections with the small apitops phosphorylcholine as antigen Johan Frostagafic Couldn't attend, Pritan kunar Panda', Shallesh Samal' *Karaninska Institutet, Sweden *Uppsala University, Sweden  12:00-12:15  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChadOx-1 and BNT162b2 Zoitan Banki', Jose Mateus', Annika Rössler', Helena Schäfer', David Bante', Lydia Ripeler', Alba Garfioni', Alessandro Sette-1', Ivviana Simons*** Sarbara Falkensammer', Hanno Ulmer', Banca Neurauter', Wegene Borena', Florian Krammer'a', Dorothee von Laer', Daniela Michael Michael St.  "Inviersity of Celifornio, San Diega (UCSD), USA.  "Popartment of Medicine at Mount Sinal, USA.  "Popartment of Medicine	10:00-10:30	· · · · · · · · · · · · · · · · · · ·	
11:30-13:00  Refreshment break Room: Refreshment break Room: Garda  11:30-13:00  REAKOUT SESSION 12 Hot Topics Chair: Florian Krammer, Rick Kennedy Room: Garda  11:30-12:00  INV 31 - Mucosal vaccination for SARS-CoV-2 ellicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern Ashley St. John, Duke – NUS Medical School, Singapore  12:00-12:15  O11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphorylcholine as antigen Inhan Frosterated Couldn't attend, Pritam Kumar Panda', Shallesh Samail 'Korolinska Institute, Sweden 'Uppsala University, Sweden  O11.2 - The pragmatic, muiti-center, three-arm, partially randomized HEVACC trial: Heterologous Ashaecs, Country (Audos), John Michael Schäere', David Bante', Lydia Riepler', Alha Grifoni', Alessandro Settra <sup>2</sup> , Visiona Simons*2-82, Bathsan Schäere', David Bante', Lydia Riepler', Alha Grifoni', Alessandro Settra <sup>2</sup> , Visiona Simons*2-82, Bathsan Falkensammer', Hanno Ulmer', Bianca Neurauter', Wegene Borena', Haorian Krammer's, Dorothee von Laer', Daniela Weiskopf', Jamine Kimpel'  'Medicol Ulniversity of Instituce, Sundon School of Medicine at Mount Sinai, USA. 'Pregortment of Pathology, Icohn School of Medicine at Mount Sinai, USA. 'Pre Globol Health and Emerging Pathogen Institute, Icohn School of Medicine at Mount Sinai, USA. 'Pre Globol Health and Emerging Pathogen Institute, Icohn School of Medicine at Mount Sinai, USA. 'Pre Globol Health and Emerging Pathogen Institute, Icohn School of Medicine at Mount Sinai, USA. 'Pre Globol Health and Emerging Pathogen Institute, Icohn School of Medicine at Mount Sinai, USA. 'Pre Globol Health and Emerging Pathogen Institute, Icohn School of Medicine at Mount Sinai, USA. 'Pre Globol Health and Emerging Pathogen Institute, Icohn School of Medicine at Mount Sinai, USA. 'Pre Globol Health and Emerging Pathogen Institute, Icohn School of Medicine at Mount Sinai, USA. '	10:30 11:00		
11:30-13:00  BREAKOUT SESSION 12 Hot Topics Chair: Borian Krammer, Rick Kennedy Room: Belower Chair: Borian Krammer, Rick Kennedy Room: Selower Chair: Borian Krammer, Rick Kennedy Room: Carda  11:30-12:00  IN V11 - Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutraling antibodies against variants of concern Ashley St. John, Duke – NUS Medical School, Singapore  12:00-12:15  O11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small ephose phosphorytholnine as a mitgen Johan Frostexial Couldn't attend, Pritam Kumar Panda's, Shalesh Samal' 'Korolisak Institutet, Sweden 'Uppsalo University, Sweden  Vappsalo University, Sweden  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT152b2 Zoltan Banki', Jose Mateus', Annika Rössler', Helena Schäter', David Bante', Lydia Riepler', Alba Grifoni', Alessandro Settra', Viviana Simperit', Organical Betwen, Jalassans Kelta', Marianne Chemaly' Megene Borena', Biorian Krammer', Dorothee Methodox or under the Medical University of Innistruck, Austria.  12:15-12:30  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT152b2 Zoltan Banki', Jose Mateus', Annika Rössler', Helena Schäter', David Bante', Lydia Riepler', Alba Grifoni', Alessandro Settra', Viviana Simperit's Organical Research Lord (RICK), Spoin "Retrobage Bosque Foundation for Science, Spoin." CIBERend, Instituto de Sould Cartos (M. Spoin Retrobage) Sould Cartos (M. Spoin	10:30-11:00		-income countries
11:30-13:00    ReakOUT SESSION 12	11:00-11:30		
Hot Topics Chair: Florian Krammer, Rick Kennedy Room: Gordo 11:30-12:00 11:30-			
Chairs: Florian Krammer, Rick Kennedy Room: Gordo Room: Gordo Room: Gordo Room: Dolomiti 11:30-12:00 INV 11 - Mucosal vaccination for SARS-CoV-2 elicits superior systemic Central memory function and cross-neutraling antibodies against variants of concern Ashley St. John, Duke – NUS Medicol School, Singapore  12:00-12:15  O11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphorylcholine as antigen Johan Frostegård: Couldn't attend, Pritam Kumar Panda', Shallesh Samal' Karolinska Institutet, Sweden **Uppsala University, Sweden  Sweden **Uppsala University, Sweden  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2 Zoltan Bankli', Jose Mateus', Annika Rössler', Helens Schäfer', David Bante', Lydia Riepler', Alba Grifoni', Alessandro Sette-', Viviana Simons'- <sup>5-16</sup> , Barbara Falkensammer', Hanno Ulmer', Banca Neurauter', Wegene Borena', Florian Krammer's', Dorothee von Laer', Daniela Weiskopf', Jainnie Kingel'  **Medical University of Innsbruck, Austria. **Center for Infectious Disease and Vaccine Research, Ill Use. **Color Medicine at Mount Sinal, USA.** **Opeopatment of Medicine at Mount Sinal, USA.** **Olor Medicine at Mount Sinal, USA.** **Opeopatment of Medicine at Mount Sinal, USA.**	11:30-13:00	BREAKOUT SESSION 12	BREAKOUT SESSION 13
Room: Dolomiti   Nov 11 - Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern   Ashley St. John, Duke – NUS Medical School, Singapore   12:00-12:15   O11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphorylcholine as antigen   Iohan Frostagardi Couldn't attend, Pritam Rumar Panda', Shallesh Samali-Ykorolinska Institutet, Sweden <sup>3</sup> Uppsala University, Sweden   Sweden <sup>3</sup> Uppsala University, Sweden   Amount Sinal, USA, Sandra Marker, Center (Intel Coloratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Loboratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Research Center (INAC-SA), Spain: Retrospacye, Basque Foundation for Science, Spain: **OIEBRehd, Institute de Salud Cardos III, Spain and Macrophage Plasticit, Loboratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Research Center (INAC-SA), Spain: Retrospacye, Basque Foundation for Science, Spain: **OIEBRehd, Institute de Salud Cardos III, Spain and Macrophage Plasticit, Loboratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Research Center (INAC-SA), Spain: Retrospacye, Basque Foundation for Science, Spain: ***OIEBRehd, Institute de Salud Cardos III, Spain and Macrophage Plasticit, Loboratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Research, Largos Retrospacye, Basque Foundation for Science, Spain: ***OIEBRehd, Institute de Salud Cardos III, Spain and Macrophage Plasticit, Loboratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Research, Largos Retrospacye, Basque Foundation for Science, Spain: ***OIEBRehd, Institute de Salud Cardos III, Spain and Macrophage Plasticit, Loboratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Research, Largos Retrospacye, Basque Foundation for Science, Spain: **OIEBRehd, Institute de Salud Cardos III, Spain and Macrophage Plasticit, Loboratory, CC bioGUNE-BRTA, Spain: Animal Heiotic Retrospacye, Basque Foundation for Fetct of vaccination and Macrop		·	
11:30-12:00  INV 11 - Mucosal vaccination for SARS-Co-V-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern Ashley St. John, Duke – NUS Medical School, Singapore  12:00-12:15  12:00-12:15  11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including could-19 and other viral infections including could-19 and other viral infections with the small epitope phosphorylcholine as antigen Johan Frostegård' Couldn't attend, pritam Kumar Panda', Shallesh Samal' *Kerolinska Institute, Sweden *Uppsalo University, Sweden  12:00-12:15  12:15-12:30  10.11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-Co-V 2 vaccination with ChAdOx-1 and BNT162b2  20.11.3 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-Co-V 2 vaccination with ChAdOx-1 and BNT162b2  20.11.3 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-Co-V 2 vaccination with ChAdOx-1 and BNT162b2  20.11.3 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-Co-V 2 vaccination with ChAdOx-1 and BNT162b2  20.11.3 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-Co-V 2 vaccination with ChAdOx-1 and BNT162b2  20.11.3 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-Co-V 2 vaccination with ChAdOx-1 and BNT162b2  20.12.3 - The effect of vaccination against Campylobacter on gut immune responses and Sarchive (Austria) Control (Austria) Campylobacter on gut immune responses and Carriol Book Michael Statistics, Medical University of Proof, Machine of Medicine at Mount Sinal, USA. "Perportment of Medicine at Mount Sinal, USA. "Perportment of Pathology, Lanns Kimol of Medicine at Mount Sinal, USA. "Perportment of Medicine at Mount Sinal, USA. "Perportment of Medicine at Mount Sinal, USA. "Perportment of Medicine a		·	
superior systemic T central memory function and cross-neutralizing antibodies against variants of concern Ashley St. John, Duke – NUS Medical School, Singapore  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  13:1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphorylcholine as antigen Johan Prostegard's Couldn't attend, Pritam Kumar Panda's, Shailesh Samal' 'karolinska Institutet, Sweden 'Uppsala University, Sweden 'Uppsala University of Uppsala	44.20.42.00		
cros-neutralizing antibodies against variants of concern Ashley St. John, Duke – NUS Medical School, Singapore  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:15  12:00-12:16  12:00-12:15  12:00-12:16  12:00-12:1	11:30-12:00		,
concern Ashley St. John, Duke – NUS Medical School, Singapore  12:00-12:15  12:00-1			<u> </u>
12:00-12:15  O11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphory/choline as antigen lohan Frostegård¹ Couldn't attend, Pritam Kumar Panda³, Shailesh Samai¹ 'Korolinska Institutet, Sweden ³Uppsola University, Sweden Sweden ³Uppsola University, Sweden Gell-mediated T CD8+ protection in IFNAR -/- mice. Sahrie Guerra', Diego Barriales, Gema Lorenzo³, Sandra Moreno³, Juan Anguita², Alejandro Brun³, Nicola Abrescia¹, Aspain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE-BRTA, Spain. ³animal Health Research Center (INIA-CISA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE-BRTA, Spain. ³animal Health Research Center (INIA-CISA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE-BRTA, Spain. ³animal Health Research Center (INIA-CISA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE-BRTA, Spain. ³animal Health Research Center (INIA-CISA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE, Branc And Technology Alliance (BRTA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE, Branc And Technology Alliance (BRTA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE, Branc And Technology Alliance (BRTA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE, Branc And Technology Alliance (BRTA), Spain. ¹animation and Macrophage Plasticite Laboratory, CIC bioGUNE, Branc And Technology Alliance (BRTA), Spain. ¹animation and macrophage Plasticite Laboratory, CIC bioGUNE, Branc And Technology Alliance (BRTA), Spain. ¹animation and Technology Alliance (BRTA), Spain. ¹animation and Technology Alliance (BRTA), Spain. ¹animation and Technology Alliance (BRTA),			Tresentation will be given remotely
12:00-12:15  O11.1 - A vaccine candidate against atherosclerosis, chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphorytcholine as antigen loban Frostegard' Couldn't attend, Pritam Kumar Panda', Shailesh Samal' *Karolinska Institutet, Sweden *Uppsala University, Sweden  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-Cov-2 vaccination with ChAdox-1 and BNT162b2  Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette¹-²³, Viviana Simons**5.**, Barbara Falkensammer³, Hanno Ulmer³, Blanca Neurauter¹, Wegene Borena¹, Florian Krammer⁴s, Dorothee von Laer¹, Daniela Weiskopf¹, Janine Kimpel¹  *Medical University of Innsbruck, Austria *Center for Infectious Disease and Vaccine Research, LI USA. **Dupartment of Pathology, Icahn School of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai, USA. **Department of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai, USA. **Department of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai, USA. **Dusison of Infectious Diseases, Jeahn School of Medicine at Mount Sinai		Ashley St. John, Duke – NUS Medical School,	
chronic inflammation and infections including covid-19 and other viral infections with the small epitope phosphorylcholine as antigen lohan Frostegård' Couldn't attend, Pritam Kumar Panda', Shailesh Samal' *Korolinska Institutet, Sweden *Uppsala University, Sweden *Cic bioGune. Bark: Laboratory, Cic bioGune. Bark: Laboratory, Cic bioGune. Bark: Joen and Technology Alliance (BRTA), Spain. *Inflammation and Macrophage Plasticit, Laboratory, Cic bioGune. Bark: Joen. *Animal Health Research Center (INNA-CISA), Spain. *Nerbasque, Bosque Foundation for Science, Spain. *Cic BioGune. Bark, Spain. *Nahimal Health Research Center (INNA-CISA), Spain. *Nahimal Health Ages and Cardon III. Spain Spain. *Nahimal Health Ages and Center Spain Spain. *Nahimal Health Ages and Center Spain Spain. *Nahimal Health Ages and Center Spain Spain Spain. *Nahimal Health and Spain S			
covid-19 and other viral infections with the small epitope phosphoryhcholine as antigen Ishan Frostegård! Couldn't attend, Pritam Kumar Panda <sup>2</sup> , Shailesh Samal <sup>11</sup> 'Korolinska Institutet, Sweden <sup>2</sup> Uppsala University, Sweden Colonia (BRTA), Spain <sup>2</sup> 'Inflammation and Macrophage Plasticit, Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Spain <sup>2</sup> Inflammation and Macrophage Plasticit, Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Spain <sup>2</sup> Inflammation and Macrophage Plasticit, Laboratory, CIC bioGUNE, BRTA, Spain <sup>3</sup> Animal Health Abresach Content (INIAL-CISA) and Stafer Joanially randomized HEVACC trial: Heterologous SARS-COV-2 vaccination with ChAdOx-1 and BNT162b2  Zoltan Banki <sup>1</sup> , Jose Mateus <sup>2</sup> , Annika Rössler <sup>2</sup> , Helena Schäfer <sup>1</sup> , David Bante <sup>1</sup> , Lydia Riepler <sup>1</sup> , Alba Grifoni <sup>2</sup> , Alessandro Sette <sup>2-3</sup> , Viviana Simons <sup>4,5,6,7</sup> , Barbara Falkensammer <sup>1</sup> , Hanno Ulmer <sup>8</sup> , Bianca Neurauter <sup>1</sup> , Wegene Borena <sup>1</sup> , Florian Krammer <sup>4,5</sup> , Dorothee von Laer <sup>1</sup> , Daniel Weiskopf <sup>1</sup> , Janine Kimpel <sup>1</sup> *Medical University of Innsbruck, Austria. *Center for Infectious Disease and Vaccine Research, LII USA.  **Juniversity of California, San Diego (UCSD), USA. **Alcaha School of Medicine at Mount Sinai, USA. *Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. *Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. *Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  12:30-12:45  O11.3 - The vaccine Trust Gauge – Assessment of Pathology, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge – Assessment of Accine Trust Gauge – Assessment of Avaccine Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Masoud, Alanna Kate Cruz, Scott Ratzan  Cell-mediated Crust Version Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Cell-mediated Crust Version Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan	12:00-12:15	O11.1 - A vaccine candidate against atherosclerosis,	
epitope phosphorylcholine as antigen  Ighan Frostegard' Couldn't attend, Pritam Kumar Panda', Shaliesh Samal'i Kroorlinska Institutet, Sweden <sup>2</sup> Uppsala University, Sweden  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-COV-2 vaccination with ChAdOx-1 and BNT162b2 Zoltan Bankii', Jose Mateus <sup>2</sup> , Annika Rössler <sup>1</sup> , Helena Schäfer <sup>2</sup> , David Bante <sup>1</sup> , Lydia Riepler <sup>1</sup> , Alba Grifoni <sup>2</sup> , Alessandro Sette <sup>2,3</sup> , Viviana Simons <sup>4,5,6</sup> , Barbara Falkensammer <sup>2</sup> , Hanno Ulmer <sup>8</sup> , Blanca Rourauter <sup>1</sup> , Wegene Borena <sup>3</sup> , Florian Krammer <sup>4,5</sup> , Dorothee von Laer <sup>2</sup> , Daniel Weiskopf <sup>2</sup> , Janine Kimpel <sup>1</sup> 1-Medical University of Innsbruck, Austria. <sup>2</sup> Center for Infectious Disease and Vaccine Research, LII USA. <sup>3</sup> University of California, San Diego (UCSD), USA. <sup>4</sup> Icahn School of Medicine at Mount Sinai, USA. <sup>5</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. <sup>5</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. <sup>5</sup> Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  12:45-13:00  O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Assoud, Alanna Kate Cruz, Scott Ratzan  Gabriel Guerra <sup>3</sup> , Diaca Moreas, Juan Anguita <sup>3</sup> , Alejandro Brund Vince (Ell Biology of Viruses Lob. Sandra Moreno <sup>3</sup> , Juan Anguita <sup>3</sup> , Nacian Anterial Barbar Alepiandro Brund Finai, Nicola Abrescia- <sup>4,5</sup> Structur and Cell Biology of Viruses Lob. CIC bioGUNE, Bara, Juan Anguita <sup>3</sup> , Dianina (Ell Biology of Viruses Lob. CIC bioGUNE, Bara, Juan Anguita <sup>3</sup> , Dianina Heolth Research Center (Inval-Cisal), Spain. <sup>4</sup> Ikerbasque, Bospain. <sup>4</sup>			
Sandra Moreno³, Juan Anguita³, Alejandro Brun³, Nicola Abrescia¹ Structure and Cell Biology of Viruses Lab, Sweden ²Uppsala University, Sweden (BRTA), Spain. ³Infiammation and Macrophage Plasticit Laboratory, CIC bioGUNE-BRTA, Spain. ³Animal Health Research Center (INIA-CISA), Spain. ³Nerbasque, Basque Foundation for Science, Spain. ³CIBERehd, Instituto de Salud Carlos III, Spain on Center (INIA-CISA), Spain. ³Nerbasque, Basque Foundation for Science, Spain. ³CIBERehd, Instituto de Salud Carlos III, Spain on Carlos Basque, Basque Foundation for Science, Spain. ³CIBERehd, Instituto de Salud Carlos III, Spain on			•
Panda <sup>2</sup> , Shailesh Samal <sup>1-1</sup> Karolinska Institutet, Sweden <sup>2</sup> Uppsala University, Sweden  Appearation of the state of the			
CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Spain. ¹Inflammation and Macrophage Plasticit Laboratory, CIC bioGUNE-BRTA, Spain. ¹Animal Health Research Center (INIA-CISA), Spain. ¹Aliamal Health Assauld Carolis III, Spain Central Binator III, Spain. ¹Aliamal Health Research Center (INIA-CISA), Spain. ¹Aliamal Health de Salud Carolis III, Spain. ¹Aliamal Health Research Center (INIA-CISA), Spain. ¹Aliamal Health de Salud Carolis III, Spain. ¹Aliamal Health Assaul, Spain. ¹Aliamal Health de Salud Carolis III, Spain. ¹Aliamal Health assaul Carolis III, Spain. ¹Aliamal Health Assaul, Alassaun Carolis III, Spain. ¹Aliamal Health assaul Carolis III, Spain. ¹Aliamal Health assaul Carolis III, Spain. ¹Aliamal Health Assaul, Carolis III, Spain. ¹Aliamal Health Assaul, Carolis III, Spain. ²Aliamal Health Assaul, Carolis III, Spain. ²Aliamal Health Assaul, Carolis III, Spain. ²Aliamal Microbiota composition in chickens Noémic III, Spain. ²Aliamal Microbiota composition in chickens Noémic III, Spain. ²Aliamal Microbiota composition in chickens Noémic III, Spain. ²Aliamal Microbiota composition of infectous Disease. ²Aliamal Peria, Daniel Microbiota composition in chickens Noémic III, Spain. ²Aliamal Microbiota composition of infectous Disease, Alassaun Assaul Alassaun Assaul Carolis III, Spain. ²Aliamal Peria, Daniel Microbiota, Palassaun Assaul Alassaun Assaul Alassaun Assaul Alassaun Assaul Al			_ =
(BRTA), Spain. <sup>2</sup> Inflammation and Macrophage Plasticit, Laboratory, CLC bioGUNF-BRTA, Spain. <sup>3</sup> Animal Health Research Center (INIA-CISA), Spain. <sup>3</sup> Animal Health Research Center (INIA-CISA), Spain. <sup>3</sup> Animal Health Sound Carlos III, Spain SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2 Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni¹, Alessandro Sette²³, Iviana Simons¹, Sa³, Barbara Falkensammer¹, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena¹, Florian Krammer⁴s⁵, Dorothee von Laer¹, Daniela Weiskopf³, Janine Kimpel¹ <sup>1</sup> Medical University of Innsbruck, Austria. <sup>2</sup> Center for Infectious Disease and Vaccine Research, LII USA. <sup>3</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. <sup>3</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. <sup>3</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. <sup>3</sup> Department of Medical Statistics, Medical University of Innsbruck, Austria <sup>2</sup> Center Boron of Medicine at Mount Sinai, USA. <sup>3</sup> Department of Medical Statistics, Medical University of Innsbruck, Austria <sup>2</sup> O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Ting Central Bank of Malaysia, Malaysia <sup>4</sup> Central Bank of Malaysia, Malaysia <sup>4</sup> O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan <sup>5</sup> Cott Ratz			
12:15-12:30  10:11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2  2 Zoltan Banki³, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴5.56.7 Barbara Falkensammer³, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena¹, Florian Krammer³-5, Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹³ dedical University of Innisbruck, Austria. *2Center for Infectious Disease and Vaccine Research, LII USA. *3University of California, San Diego (UCSD), USA. *1cahn School of Medicine at Mount Sinai, USA. *Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. *Department of Medical Statistics, Medical University of Innisbruck, Austria  12:30-12:45  12:30-12:45  12:45-13:00  12:45-13:00  12:13-1-The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous Sange Accovation with ChAdOx-1 and BNT162b2  2011.2 - The effect of vaccination against Compulpobacter on gut immune responses and microbiota composition in chickens Medical Guestia, Marianne Chemaly² Veronique Béven³, Alassane Keita⁴, Marianne Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Environmental and Occupational Health and Safety (ANSES), France. *3UFR of Life Sciences Environment, University of Rennes 1, France *3ELEAC - Avian breeding and experimental Department (ANSES), France  (ANSES), France  12:30-12:45  12:30		Sweden Oppsaid Oniversity, Sweden	
Touristive de Solud Carlos III, Spain  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2  Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴5.67, Barbara Falkensammer³, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena³, Florian Krammer⁴s, Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹¹ Aldedical University of Innsbruck, Austria. *Center for Infectious Disease and Vaccine Research, LII USA. *3 University of California, San Diego (UCSD), USA. *3 Centent of Pathology, Icahn School of Medicine at Mount Sinai, USA. *3 Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. *3 Department of Medical Statistics, Medical University of Innsbruck, Austria *Central Bank of Medicine at Mount Sinai, USA. *3 Department of Medical Statistics, Medical University of Innsbruck, Austria *Central Bank of Medicysia, Malaysia *Central Bank of Molaysia, Malaysia *Central Bank			1, , , , , , , , , , , , , , , , , , ,
12:15-12:30  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-COV-2 vaccination with ChAdOx-1 and BNT162b2  Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴.5.6.7, Barbara Falkensammer³, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena¹, Florian Krammer⁴.5 Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹¹ Amedical University of Innsbruck, Austria. Center for Infectious Disease and Vaccine Research, LII USA. ¹ Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ¹ Department of Medical Statistics, Medical University of Innsbruck, Austria  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches  P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Salud Carlos III, Spain Cather for multicons of put dicine at microbiota composition in chickens Macrophologater on gut immune responses and microbiota composition in chickens Mocrophologater on gut immune responses and microbiota composition in chickens Mocrophologater on gut immune responses and microbiota composition in chickens Mocrophologater on gut immune responses and microbiota composition in chickens Mocrophologater on gut immune responses and microbiota composition in chickens Mocrophologater on gut immune responses and microbiota composition in chickens Mocrophologater on gut immune responses and microbiota composition in chickens Mocrophologater on gut immune responses and microbiota composition in chickens Mocrophologate Abeven¹, Alassane Keita¹, Nariane Chemaly³ Véronique Béven¹, Alassane Keita¹, Nariane Catheron (ANSES), France ³ PLOPAP (ANSES), France ³ PLOPAP (ANSES), France ³ PLOPAP (A			Research Center (INIA-CISA), Spain. <sup>4</sup> Ikerbasque, Basque
12:15-12:30  O11.2 - The pragmatic, multi-center, three-arm, partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2  Zoltan Banki³, Jose Mateus², Annika Rössler¹, Helena Schäfer³, David Bante¹, Lydia Riepler⁴, Alba Grifoni³, Alessandro Sette²³, Viviana Simons⁴, Sōñ, Barbara Falkensammer³, Hanno Ulmer³, Bianca Neurauter³, Wegene Borena¹, Florian Krammer⁴, Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹  ¹Medical University of Innsbruck, Austria. ²Center for Infectious Disease and Vaccine Research, LII USA. ³University of Colifornia, San Diego (UCSD), USA. ¹Loahn School of Medicine at Mount Sinai, USA. ³Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ³Department			
partially randomized HEVACC trial: Heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2  Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴, Señ, Barbara Falkensammer¹, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena¹, Florian Krammer⁴, Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹  ¹Medical University of Innsbruck, Austria. ²Center for Infectious Disease and Vaccine Research, LII USA. ³University of California, San Diego (UCSD), USA. ¹Icahn School of Medicine at Mount Sinai, USA. ¹Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ¹Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ¹Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Campylobacter on gut immune responses and microbiota composition in chickens Noémic Gloanect.³, Véronique Béven¹, Alassane Keita⁴, Marianne Chemaly² Meónic Gloanect.³, Daniel Dory¹, Ségolène Quesne?, Véronique Béven¹, Alassane Keita⁴, Marianne Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Environique Béven¹, Alassane Keita⁴, Marianne Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Environique Béven¹, Alassane Keita⁴, Marianne Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Environique Béven¹, Alassane Keita⁴, Mariane Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Environique Béven¹, Alassane Keita⁴, Mariane Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Environique Béven¹, Alassane Keita⁴, Mariane Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Env			
SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2 Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴, 5.6.7, Barbara Falkensammer¹, Hanno Ulmer², Bianca Neurauter¹, Wegene Borena¹, Florian Krammer⁴s, Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹¹Medical University of Innsbruck, Austria. ²Center for Infectious Disease and Vaccine Research, LII USA. ³University of California, San Diego (UCSD), USA. ⁴Icahn School of Medicine at Mount Sinai, USA. ⁵Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ⁵Department of Medicine at Moun	12:15-12:30		I
BNT162b2 Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴.56.7, Barbara Falkensammer³, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena², Florian Krammer⁴.5, Dorothee von Laer², Daniela Weiskopf², Janine Kimpel¹ ¹Medical University of Innsbruck, Austria. ²Center for Infectious Disease and Vaccine Research, LII USA. ³University of California, San Diego (UCSD), USA. ⁴Icahn School of Medicine at Mount Sinai, USA. ¹Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ¹Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, USA. ¹Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Molaysia, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Noémie Gloanec.¹1.2.3, Daniel Dory¹, Ségolène Quesne², Véronique Béven¹, Alassane Keita⁴, Marianne Chemaly² Muriel Guyard² ¹GVB, French Agency for Food, Environmental and Occupational Health and Safety (AMSES), France. ³URQ PAP (ANSES), Franc		·	
Zoltan Banki¹, Jose Mateus², Annika Rössler¹, Helena Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴⁵.6.7, Barbara Falkensammer¹, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena¹, Florian Krammer⁴.⁵, Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹  ¹Medical University of Innsbruck, Austria. ²Center for Infectious Disease and Vaccine Research, LII USA.  ³University of Collifornia, San Diego (UCSD), USA.  ¹Icahn School of Medicine at Mount Sinai, USA.  ³Department of Pathology, Icahn School of Medicine at Mount Sinai, USA.  ³Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP  Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches  P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Véronique Béven¹, Alassane Keita⁴, Marianne Chemaly² Muriel Guyard² ¹GVB, France. ³URB, France.  ½VER of Life (VANSES), France. ³LHR por Infectious Diseases, Environment, University of Rennes 1, France  *SELEAC - Avian breeding and experimental Department (ANSES), France.  ¹SELEAC - Avian breeding and experimental Department (ANSES), France.  ¹SELEAC - Avian breeding and experimental Department (ANSES), France.  ¹SELEAC - Avian breeding and experimental Department of university of Innsbruck, Austria.  O12.3 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines Miguel			I
Schäfer¹, David Bante¹, Lydia Riepler¹, Alba Grifoni², Alessandro Sette²³, Viviana Simons⁴,5,6,7, Barbara Falkensammer¹, Hanno Ulmer³, Bianca Neurauter¹, Wegene Borena¹, Florian Krammer⁴.5, Dorothee von Laer¹, Daniela Weiskopt², Janine Kimpel¹ ¹Medical University of Innsbruck, Austria. ²Center for Infectious Disease and Vaccine Research, LII USA. ³University of California, San Diego (UCSD), USA. ¹Icahn School of Medicine at Mount Sinai, USA. ³Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. 6Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, USA. ³Department of Medicine at Mount Sinai, USA. ³Departm			
Falkensammer¹, Hanno Ulmer®, Bianca Neurauter¹, Wegene Borena¹, Florian Krammer⁴.⁵, Dorothee von Laer¹, Daniela Weiskopf², Janine Kimpel¹ ¹Medical University of Innsbruck, Austria.²Center for Infectious Disease and Vaccine Research, LII USA. ³University of California, San Diego (UCSD), USA. ⁴Icahn School of Medicine at Mount Sinai, USA. ⁵Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ⁵Division of Infectious Diseases, , Icahn School of Medicine at Mount Sinai, USA. ⁵Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  12:30-12:45  12:45-13:00  13:4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches  P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  (ANSES), France.  (ANSES), France  (SELEAC - Avian breeding and experimental Department (ANSES).  (ANSES), France  (SELEAC - Avian breeding and experimental Depar			1
Wegene Borena <sup>1</sup> , Florian Krammer <sup>4,5</sup> , Dorothee von Laer <sup>1</sup> , Daniela Weiskopf <sup>2</sup> , Janine Kimpel <sup>1</sup> <sup>1</sup> Medical University of Innsbruck, Austria. <sup>2</sup> Center for Infectious Disease and Vaccine Research, LII USA. <sup>3</sup> University of California, San Diego (UCSD), USA. <sup>4</sup> Icahn School of Medicine at Mount Sinai, USA. <sup>5</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. <sup>6</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. <sup>8</sup> Department of Medicial Statistics, Medical University of Innsbruck, Austria  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O11.3 - Reroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines  Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design  Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
Laer¹, Daniela Weiskopt², Janine Kimpel¹  ¹ Medical University of Innsbruck, Austria. ¹ Center for Infectious Disease and Vaccine Research, LII USA.  ³ University of California, San Diego (UCSD), USA.  ¹ Icahn School of Medicine at Mount Sinai, USA. ¹ Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ¹ Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. ¹ Department of Medicial Statistics, Medical University of Innsbruck, Austria  12:30-12:45  12:30-12:45  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  A SELEAC - Avian breeding and experimental Department (ANSES), France   4 SELEAC - Avian breeding and experimental Department (ANSES), France  (ANSES), France  (ANSES), France  (ANSES), France			
1-Medical University of Innsbruck, Austria. 2-Center for Infectious Disease and Vaccine Research, LII USA. 3 University of California, San Diego (UCSD), USA. 4 Icahn School of Medicine at Mount Sinai, USA. 5 Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. 6 Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. 7 Department of Medicine at Mount Sinai, USA. 8 Department of Medicine at Mount Sinai, USA. 8 Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  12:30-12:45  12:30-12:45  12:45-13:00  12:45-13:00  13 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00  13 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile 12:45-13:00  14 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  15 - Mount Sinai, USA. 16 - Mount Sinai, USA. 17 - The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA. 17 - The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA. 18 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines 19 - Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile 10 - 12 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design 19 - Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			· · · · · · · · · · · · · · · · · · ·
Infectious Disease and Vaccine Research, LII USA.  3 University of California, San Diego (UCSD), USA. 4 Icahn School of Medicine at Mount Sinai, USA. 5 Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. 6 Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, USA. 7 The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA. 8 Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  In Il USA.  4 Icahn School of Medicine at Mount Sinai, USA. 5 Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. 7 The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA. 8 Department of Medicine at Mount Sinai, USA. 8 Department of Medicine at Mount Sinai, USA. 8 Department of Medicine at Mount Sinai, USA. 9 Department of Medical Statistics, Medical University of Innsbruck, Icahn School of Medicine at Mount Sinai, USA. 9 Department of Medical Statistics, Medical University of Innsbruck, Icahn School of Medicine at Mount Sinai, USA. 9 Department of Medical Stat			<u> </u>
3 University of California, San Diego (UCSD), USA. 4 Icahn School of Medicine at Mount Sinai, USA. 5 Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. 6 Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, USA. 7 The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA. 8 Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45 O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Ing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00 O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			(ANSES), Flutice
Alcahn School of Medicine at Mount Sinai, USA.  Department of Pathology, Icahn School of Medicine at Mount Sinai, USA. Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, USA.  Repartment of Medicine at Mount Sinai, USA.  Pepartment of Medicine at Mount Sinai, USA.  Across-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Ing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  Ping Lian Suah, Molaysia, Malaysia  Traingular Biotech, Chile  12:45-13:00  O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  Academic Medicine at Mount Sinai, USA.  O12.3 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-lbáñez, Natalia Delgado, Sabrina			
SDepartment of Pathology, Icahn School of Medicine at Mount Sinai, USA. SDivision of Infectious Diseases, , Icahn School of Medicine at Mount Sinai, USA. The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA.  BDepartment of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
, Icahn School of Medicine at Mount Sinai, USA. <sup>7</sup> The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA. <sup>8</sup> Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP  Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina		<sup>5</sup> Department of Pathology, Icahn School of Medicine	
Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, USA.  *Department of Medical Statistics, Medical University of Innsbruck, Austria  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O12.3 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
Icahn School of Medicine at Mount Sinai, USA.   **Department of Medical Statistics, Medical University of Innsbruck, Austria**  12:30-12:45   O11.3 - Lives and Livelihood, Not Quite a Trade-Off:   A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP   Jing Lian Suah, Boon Hwa Tng		1.	
**Department of Medical Statistics, Medical University of Innsbruck, Austria**  12:30-12:45  O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00  O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O12.3 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
12:30-12:45 O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00 O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O12.3 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
12:30-12:45 O11.3 - Lives and Livelihood, Not Quite a Trade-Off: A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00 O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  O12.3 - Peroxynitrite is an inactivating and immunostimulating agent in the formulation of inactivated Piscirickettsia salmonis vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
A Cross-Country Analysis of the Short-Term Macro Effects of COVID-19 Mortality on Real GDP Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia  12:45-13:00 O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan  immunostimulating agent in the formulation inactivated Piscirickettsia salmonis vaccines Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile  O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina	12:30-12:45		O12.3 - Peroxynitrite is an inactivating and
Jing Lian Suah, Boon Hwa Tng Central Bank of Malaysia, Malaysia   Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile     12:45-13:00   O11.4 - The Vaccine Trust Gauge — Assessment of vaccine trust level for tailored communication approaches   P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan   Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina   Miguel Del Campo, Sergio Arancibia, Cristian Silva Traingular Biotech, Chile     O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2   Leptospira spp. isolates from Colombia: implications   for vaccine design   Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina   Camila Renjifo-Ibáñez, Natal	- 3 <u></u> 3.	A Cross-Country Analysis of the Short-Term Macro	immunostimulating agent in the formulation of
12:45-13:00 O11.4 - The Vaccine Trust Gauge – Assessment of vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, Scott Ratzan O12.4 - Secreted immunoreactive moonlighting proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
vaccine trust level for tailored communication approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, <u>Scott Ratzan</u> proteins from pathogenic - P1 and intermediate - P2 Leptospira spp. isolates from Colombia: implications for vaccine design Camila Renjifo-Ibáñez, Natalia Delgado, Sabrina			
approaches P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, <u>Scott Ratzan</u> Leptospira spp. isolates from Colombia: implications for vaccine design <u>Camila Renjifo-Ibáñez</u> , Natalia Delgado, Sabrina	12:45-13:00	_	
P. Chris Palmedo, Lauren Rauh, Amanda Pierz, Dima Masoud, Alanna Kate Cruz, <u>Scott Ratzan</u> for vaccine design <u>Camila Renjifo-Ibáñez</u> , Natalia Delgado, Sabrina			·
Masoud, Alanna Kate Cruz, <u>Scott Ratzan</u> <u>Camila Renjifo-Ibáñez</u> , Natalia Delgado, Sabrina		1	
			1
Simenez, nodo nenera, zigia rones		iviasouu, Maiiila Nate Cluz, <u>Stott Natzall</u>	I = =
		1	James Control of the Control of the Control

	City University of New York Graduate School of Public AGR Health and Health Policy, USA	ROSAVIA, Mosquera, Colombia	
13:00-13:15	Closing Session		
	Chairs: Greg Poland, Paolo Bonanni		
	Room: Garda		
13:30-13:40	Spotlight on Africa		
	Chair: Helena Maltezou		
	Room: Dolomiti		
13:40-14:00	SA1 - Vaccines, variants and immunity - a view from the South		
	Wendy Burgers, University of Cape Town, South Africa		
14:00-14.20	SA2 - Vaccine Manufacturing: Spotlight on Africa		
	Wilmot James <sup>1</sup> , Luc Debruyne <sup>2</sup> , Azure Makadzange <sup>3</sup> , Stavros Nicolaou <sup>4</sup> , Lewis Rubin-Thompson <sup>5</sup> , Martin Veller <sup>6</sup>		
	Amadou Sall <sup>7</sup> <sup>1</sup> Columbia University, USA <sup>2</sup> KU Leuven, Belgium. <sup>3</sup> Stanford University, USA. <sup>4</sup> Aspen Pharmacare, South Africa. <sup>5</sup> University of Rochester, USA. <sup>6</sup> University of the Witwatersrand, South Africa <sup>7</sup> Institute Pasteur,		
	Senegal		
14.20-14:40	SA3 - Capacity building and preparedness for high consequence emerging virus outbreak in west Africa		
	Miles Carroll, Oxford University, UK		
14:40-15:00	SA4 - Effect of the COVID-19 pandemic on routine immunization in Africa		
	Aisha Abubakar, International Society for Infectious Disease, USA, Ahmadu Bello University, Nigeria		
	Presentation will be given remotely		
15:00-15:20			
	WEST CAMEROON PRE-RECORDED PRESENTATION	15 1 D 5 5 1 N 16	
	Lorraine Elit <sup>1,2</sup> , Glen Afugchwi <sup>1</sup> , Calvin Ngalla <sup>3</sup> , Eric Tum <sup>4</sup> , Jo		
	<sup>1</sup> Baptist Institute of Health Sciences, Cameroon. <sup>2</sup> McMastel		
	Cameroon. <sup>4</sup> Information and Orientation Vocation Centre, Cameroon. <sup>5</sup> University of Yaounde,		
15:20-15:40	Cameroon. <sup>6</sup> Western University, Canada  Panel Discussion and Q&A		
15:20-15:40	Closing Networking and Refreshments		
15.40			
	Foyer		